DexCom, Inc. (DXCM) Shares Bought by First Trust Advisors LP

Share on StockTwits

First Trust Advisors LP boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 28.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 283,132 shares of the medical device company’s stock after purchasing an additional 63,431 shares during the period. First Trust Advisors LP’s holdings in DexCom were worth $40,499,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Morgan Stanley boosted its position in DexCom by 16.3% during the 2nd quarter. Morgan Stanley now owns 5,028,874 shares of the medical device company’s stock valued at $477,644,000 after acquiring an additional 705,072 shares in the last quarter. BlackRock Inc. boosted its position in DexCom by 5.9% during the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock valued at $390,978,000 after acquiring an additional 228,933 shares in the last quarter. Point72 Asset Management L.P. boosted its position in DexCom by 25.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,225,344 shares of the medical device company’s stock valued at $116,383,000 after acquiring an additional 246,169 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its position in DexCom by 1.7% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 596,730 shares of the medical device company’s stock valued at $56,677,000 after acquiring an additional 9,919 shares in the last quarter. Finally, Waddell & Reed Financial Inc. boosted its position in DexCom by 164.8% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock valued at $54,075,000 after acquiring an additional 354,331 shares in the last quarter.

DXCM has been the topic of several research reports. Northland Securities raised DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Stephens boosted their price target on DexCom from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Thursday, August 23rd. Canaccord Genuity boosted their price target on DexCom from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Piper Jaffray Companies boosted their price target on DexCom to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, August 2nd. Finally, BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 21st. Eight analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $129.06.

In related news, Director Nicholas Augustinos sold 12,300 shares of the company’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $121.33, for a total value of $1,492,359.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Patrick Michael Murphy sold 12,500 shares of the company’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $124.18, for a total value of $1,552,250.00. The disclosure for this sale can be found here. Insiders sold a total of 182,692 shares of company stock worth $24,908,639 over the last ninety days. 1.80% of the stock is currently owned by insiders.

Shares of DXCM opened at $132.77 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62. DexCom, Inc. has a 52 week low of $44.50 and a 52 week high of $148.56.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. The firm had revenue of $242.50 million for the quarter, compared to analysts’ expectations of $205.81 million. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. The business’s revenue for the quarter was up 42.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post -0.47 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply